Data protection Impressum

Life sciences

Following a CHF 2.4 million seed round, Bern-based medtech start-up Aseptuva has moved from early prototyping to preclinical validation of its Far-UVC technology designed to prevent catheter-related bloodstream infections, and is now raising a CHF 5 million Series A.

Aseptuva moves to preclinical validation and opens a CHF 5 million Series A round

22 September 2026

The Foundation for Innovation and Technology has awarded CHF 100,000 Tech Seed loans to Dexterous Endoscopes, for an endoscope that switches from flexible to rigid during a procedure, and to Precisia Care, for its hospital data analytics platform.

FIT grants Tech Seed loans to Dexterous Endoscopes and Precisia Care

14 September 2026

The tenth Swiss Medtech Industry Study reports a sector generating CHF 26 billion in sales and growing at twice the rate of the Swiss economy, while flagging a marked slowdown in job creation and investment. Western Switzerland accounts for a substantial share of the country's medtech base.

Swiss medtech grows twice as fast as the economy

14 September 2026

FluoSphera, the Geneva-based biotech developing advanced in vitro models, has entered a license agreement for Debiopharm's AbYlink antibody conjugation technology, combining it with light sheet microscopy from Leica Microsystems into a single workflow for antibody characterization.

FluoSphera partners with Debiopharm and Leica Microsystems

7 September 2026

An interdisciplinary team from the University of Bern and Inselspital has developed CARESCORE, an AI model that calculates a patient's individual risk of postoperative infection within seconds of surgery ending, by drawing on vital signs recorded during the procedure.

Bern researchers develop an AI model that predicts infection risk at the end of surgery

31 August 2026

Addex Therapeutics, the Geneva-based clinical-stage biotech developing small-molecule allosteric modulators for neurological disorders, has raised gross proceeds of USD 2.8 million through its at-the-market program.

Addex Therapeutics extends its cash runway into the fourth quarter of 2027

31 August 2026

Adaptyv Biosystems has closed a USD 40 million Series A round to expand the automated laboratory it operates for the rapid experimental validation of newly designed proteins.

Adaptyv raises USD 40 million for its automated protein lab

31 August 2026

Distalmotion, the Lausanne-based medtech company, has received FDA 510(k) clearance for ventral hernia repair with its DEXTER Robotic Surgery System, completing its portfolio for the four highest-volume outpatient soft tissue procedures in the United States.

Distalmotion’s DEXTER robot cleared by the FDA for ventral hernia repair

20 August 2026

Spineart, the Geneva-based medtech company specializing in spine surgery, has received FDA approval for its BAGUERA C cervical disc for one and two contiguous levels, expanding access in the United States to a motion-preserving solution for cervical disc disease.

Spineart receives FDA approval for its BAGUERA C cervical disc

20 August 2026

Oculis, the Lausanne-based biopharmaceutical company focused on ophthalmology and neuro-ophthalmology, will acquire all worldwide development and commercial rights to Privosegtor from Accure, terminating its existing license agreement.

Oculis acquires worldwide rights to its Privosegtor candidate

17 August 2026

1 2 3 4 5 … 30